z-logo
open-access-imgOpen Access
Intrathecal Amphotericin B: A 60-Year Experience in Treating Coccidioidal Meningitis
Author(s) -
Jackie Ho,
Pete Fowler,
Arash Heidari,
Royce H. Johnson
Publication year - 2016
Publication title -
clinical infectious diseases
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciw794
Subject(s) - medicine , intrathecal , dosing , amphotericin b , meningitis , lumbar puncture , complication , surgery , intensive care medicine , antifungal , cerebrospinal fluid , dermatology
Coccidioidal meningitis (CM) is a devastating complication of coccidioidomycosis. Since the late 1950s, intrathecal (IT) amphotericin B deoxycholate (AmBd) has been successfully used to treat and often cure this disease, reducing mortality rates from 100% to approximately 30%. The introduction of azoles further revolutionized the treatment of coccidioidal infections. However, IT AmBd remains the only known curative option in the management of CM. While the use of IT AmBd is well described in many articles, few discuss the actual methods behind preparation, titration, and dosing strategies utilized. The practitioners at Kern Medical (Bakersfield, California) have >60 years of experience in the utilization of IT AmBd and the treatment of CM. This article describes the practice experience in the treatment of CM, preparation of IT AmBd, and the different dosing strategies used in regard to route of administration (ie, cisternal, lumbar, ventricular).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom